Kaczmarzyk et al
It drives the transition from proliferation to differentiation and increases the number and length of multinucleated myotubes in a dosedependent manner.The mechanism is mainly related to NNMT inhibition, restored NAD levels, and activation of the SIRT1PGC1 pathway
GLP-1 medications (including FDA-approved options such as semaglutide and tirzepatide) have been associated with greater average weight loss in clinical trials
GLP-1 produces continued, compounding loss
Autoimmune and inflammatory conditions Patients with autoimmune conditions including lupus, rheumatoid arthritis, and Hashimoto thyroiditis have increasing access to GLP-1 therapy, and the anti-inflammatory mechanism provides specific rationale for this use
Fella Healths individualized care, expert clinical oversight, and results-driven approach set it apart, providing a more focused and supportive weight management program compared to the broader wellness offerings of Bioverse